Literature DB >> 22473919

Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.

David I Daikh, E William St Clair.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22473919      PMCID： PMC4097090          DOI： 10.1002/acr.21659

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN： 2151-464X            Impact factor:   4.794


× No keyword cloud information.
  9 in total

1.  The appropriateness method.

Authors:  Paul Shekelle
Journal:  Med Decis Making       Date:  2004 Mar-Apr       Impact factor: 2.583

2.  Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

Authors:  Ann Corken Mackey; Lanh Green; Li-Ching Liang; Patricia Dinndorf; Mark Avigan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-02       Impact factor: 2.839

3.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.

Authors:  Gordon H Guyatt; Andrew D Oxman; Gunn E Vist; Regina Kunz; Yngve Falck-Ytter; Pablo Alonso-Coello; Holger J Schünemann
Journal:  BMJ       Date:  2008-04-26

4.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

5.  2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery.

Authors:  Thomas G Brott; Jonathan L Halperin; Suhny Abbara; J Michael Bacharach; John D Barr; Ruth L Bush; Christopher U Cates; Mark A Creager; Susan B Fowler; Gary Friday; Vicki S Hertzberg; E Bruce McIff; Wesley S Moore; Peter D Panagos; Thomas S Riles; Robert H Rosenwasser; Allen J Taylor
Journal:  Vasc Med       Date:  2011-02       Impact factor: 3.239

6.  Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.

Authors:  Deepak Parakkal; Humberto Sifuentes; Rumi Semer; Eli Daniel Ehrenpreis
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 2.566

Review 7.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

8.  Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.

Authors:  Pauline Raaschou; Julia F Simard; Martin Neovius; Johan Askling
Journal:  Arthritis Rheum       Date:  2011-07

Review 9.  Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.

Authors:  D H Solomon; E Mercer; A Kavanaugh
Journal:  Arthritis Rheum       Date:  2012-01
  9 in total
  4 in total

1.  DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis.

Authors:  Nirit Mor-Vaknin; Anjan Saha; Maureen Legendre; Carmelo Carmona-Rivera; M Asif Amin; Bradley J Rabquer; Marta J Gonzales-Hernandez; Julie Jorns; Smriti Mohan; Srilakshmi Yalavarthi; Dave A Pai; Kristine Angevine; Shelley J Almburg; Jason S Knight; Barbara S Adams; Alisa E Koch; David A Fox; David R Engelke; Mariana J Kaplan; David M Markovitz
Journal:  Nat Commun       Date:  2017-02-06       Impact factor: 14.919

2.  Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Authors:  Teruo Murakami; Nobuhiro Mori
Journal:  Pharmaceuticals (Basel)       Date:  2012-08-10

3.  A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis.

Authors:  David A Martin; Melvin Churchill; Luis Flores-Suarez; Mario H Cardiel; Daniel Wallace; Richard Martin; Kristine Phillips; Jeffrey L Kaine; Hua Dong; David Salinger; Erin Stevens; Chris B Russell; James B Chung
Journal:  Arthritis Res Ther       Date:  2013-10-25       Impact factor: 5.156

4.  Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.

Authors:  Min Wei; Dongmei Duan
Journal:  Drug Des Devel Ther       Date:  2016-09-09       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.